NASDAQ:FPRXFive Prime Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Five Prime Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.89 -0.39 (-7.39 %) (As of 06/3/2020 04:00 PM ET) Add Compare Share Today's Range$4.78Now: $4.89▼$5.3450-Day Range$2.64MA: $3.90▼$5.9452-Week Range$1.75Now: $4.89▼$6.93Volume280,101 shsAverage Volume406,307 shsMarket Capitalization$179.15 millionP/E RatioN/ADividend YieldN/ABeta2.96 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase III clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor. The company's BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in clinical trial as a single agent and in combination with Opdivo in patients with advanced malignant tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; a collaboration agreement with Roche; and license agreements with Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California.Read More Beat the Market (BTM) Rank™ 3.0 Analyst's Opinion Consensus RatingFive Prime Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 3 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.50, Five Prime Therapeutics has a potential upside of 53.4% from its current price of $4.89.Amount of Analyst CoverageFive Prime Therapeutics has received no research coverage in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesFive Prime Therapeutics has received 291 “outperform” votes. (Add your “outperform” vote.)Underperform VotesFive Prime Therapeutics has received 237 “underperform” votes. (Add your “underperform” vote.)Community SentimentFive Prime Therapeutics has received 55.11% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Five Prime Therapeutics and other stocks. Vote “Outperform” if you believe FPRX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe FPRX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldFive Prime Therapeutics does not currently pay a dividend.Dividend GrowthFive Prime Therapeutics does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Five Prime Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,203,707.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 6.40% of the stock of Five Prime Therapeutics is held by insiders.Percentage Held by Institutions68.02% of the stock of Five Prime Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Five Prime Therapeutics are expected to grow in the coming year, from ($2.44) to ($2.02) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Five Prime Therapeutics is -1.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Five Prime Therapeutics is -1.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFive Prime Therapeutics has a P/B Ratio of 1.18. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.09 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FPRX Previous Symbol CUSIPN/A CIK1175505 Webwww.fiveprime.com Phone415-365-5600Debt Debt-to-Equity Ratio0.33 Current Ratio7.82 Quick Ratio7.82Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$14.87 million Price / Sales12.05 Cash FlowN/A Price / Cash FlowN/A Book Value$4.13 per share Price / Book1.18Profitability EPS (Most Recent Fiscal Year)($3.92) Net Income$-137,200,000.00 Net Margins-679.63% Return on Equity-72.79% Return on Assets-49.84%Miscellaneous Employees209 Outstanding Shares36,635,000Market Cap$179.15 million Next Earnings Date8/5/2020 (Estimated) OptionableOptionable NASDAQ:FPRX Rates by TradingView Receive FPRX News and Ratings via Email Sign-up to receive the latest news and ratings for FPRX and its competitors with MarketBeat's FREE daily newsletter. Five Prime Therapeutics (NASDAQ:FPRX) Frequently Asked Questions How has Five Prime Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Five Prime Therapeutics' stock was trading at $2.93 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, FPRX shares have increased by 66.9% and is now trading at $4.89. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Five Prime Therapeutics? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Five Prime Therapeutics in the last year. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Five Prime Therapeutics. When is Five Prime Therapeutics' next earnings date? Five Prime Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Five Prime Therapeutics. How were Five Prime Therapeutics' earnings last quarter? Five Prime Therapeutics Inc (NASDAQ:FPRX) issued its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.67) by $0.10. The biotechnology company had revenue of $8.41 million for the quarter, compared to analyst estimates of $6.60 million. Five Prime Therapeutics had a negative net margin of 679.63% and a negative return on equity of 72.79%. View Five Prime Therapeutics' earnings history. What price target have analysts set for FPRX? 5 equities research analysts have issued twelve-month price targets for Five Prime Therapeutics' stock. Their forecasts range from $5.00 to $10.00. On average, they anticipate Five Prime Therapeutics' stock price to reach $7.50 in the next year. This suggests a possible upside of 53.4% from the stock's current price. View analysts' price targets for Five Prime Therapeutics. Has Five Prime Therapeutics been receiving favorable news coverage? Media stories about FPRX stock have been trending very negative recently, according to InfoTrie. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Five Prime Therapeutics earned a media sentiment score of -3.1 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. View the latest news aboutFive Prime Therapeutics. Are investors shorting Five Prime Therapeutics? Five Prime Therapeutics saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 1,320,000 shares, a drop of 5.0% from the April 30th total of 1,390,000 shares. Based on an average daily volume of 372,200 shares, the short-interest ratio is currently 3.5 days. Approximately 3.7% of the company's shares are short sold. View Five Prime Therapeutics' Current Options Chain. Who are some of Five Prime Therapeutics' key competitors? Some companies that are related to Five Prime Therapeutics include Cara Therapeutics (CARA), Akero Therapeutics (AKRO), Nabriva Therapeutics (NBRV), Kadmon (KDMN), Dynavax Technologies (DVAX), Collegium Pharmaceutical (COLL), Eagle Pharmaceuticals (EGRX), Molecular Templates (MTEM), Retrophin (RTRX), ZIOPHARM Oncology (ZIOP), G1 Therapeutics (GTHX), Homology Medicines (FIXX), Provention Bio (PRVB), Vanda Pharmaceuticals (VNDA) and Assembly Biosciences (ASMB). View all competitors. What other stocks do shareholders of Five Prime Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Five Prime Therapeutics investors own include Nektar Therapeutics (NKTR), Clovis Oncology (CLVS), Sangamo Therapeutics (SGMO), TG Therapeutics (TGTX), Amarin (AMRN), Gilead Sciences (GILD), ImmunoGen (IMGN), Ionis Pharmaceuticals (IONS), Opko Health (OPK) and Anavex Life Sciences (AVXL). Who are Five Prime Therapeutics' key executives? Five Prime Therapeutics' management team includes the following people: Mr. Aron Marc Knickerbocker, Pres, CEO & Director (Age 50)Mr. Francis W. Sarena, Chief Strategy Officer & Sec. (Age 48)Dr. Helen Louise Collins, Sr. VP & Chief Medical Officer (Age 56)Dr. Peder K. Jensen, Advisor & Director (Age 64)Mr. David V. Smith, Exec. VP & CFO What is Five Prime Therapeutics' stock symbol? Five Prime Therapeutics trades on the NASDAQ under the ticker symbol "FPRX." Who are Five Prime Therapeutics' major shareholders? Five Prime Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (6.98%), Wellington Management Group LLP (3.39%), State Street Corp (1.68%), Geode Capital Management LLC (1.47%), Acadian Asset Management LLC (1.16%) and Two Sigma Advisers LP (1.14%). Company insiders that own Five Prime Therapeutics stock include Andrew T Feldstein, Bvf Partners L P/Il, Franklin M Berger and Value Fund L P Biotechnology. View institutional ownership trends for Five Prime Therapeutics. Which major investors are selling Five Prime Therapeutics stock? FPRX stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Assenagon Asset Management S.A., AQR Capital Management LLC, UBS Group AG, Tudor Investment Corp Et Al, GSA Capital Partners LLP, Wellington Management Group LLP, and State Street Corp. View insider buying and selling activity for Five Prime Therapeutics. Which major investors are buying Five Prime Therapeutics stock? FPRX stock was purchased by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Healthcare of Ontario Pension Plan Trust Fund, SG Americas Securities LLC, Two Sigma Advisers LP, Nuveen Asset Management LLC, Parametric Portfolio Associates LLC, Invesco Ltd., and Geode Capital Management LLC. Company insiders that have bought Five Prime Therapeutics stock in the last two years include Andrew T Feldstein, Bvf Partners L P/Il, and Value Fund L P Biotechnology. View insider buying and selling activity for Five Prime Therapeutics. How do I buy shares of Five Prime Therapeutics? Shares of FPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Five Prime Therapeutics' stock price today? One share of FPRX stock can currently be purchased for approximately $4.89. How big of a company is Five Prime Therapeutics? Five Prime Therapeutics has a market capitalization of $179.15 million and generates $14.87 million in revenue each year. The biotechnology company earns $-137,200,000.00 in net income (profit) each year or ($3.92) on an earnings per share basis. Five Prime Therapeutics employs 209 workers across the globe. What is Five Prime Therapeutics' official website? The official website for Five Prime Therapeutics is www.fiveprime.com. How can I contact Five Prime Therapeutics? Five Prime Therapeutics' mailing address is 111 Oyster Point Boulevard, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 415-365-5600 or via email at [email protected] This page was last updated on 6/3/2020 by MarketBeat.com Staff
